KalVista Pharmaceuticals, Inc.

KALV

US4834971032

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
10.78 ^USD	+2.76%		-6.83%	-12.00%

Apr. 22	Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	CI
Apr. 15	Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	CI

KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to NASDAQ Biotechnology Index

December 18, 2023 at 12:00 am EST

KalVista Pharmaceuticals, Inc Added to NASDAQ Biotechnology Index.

Latest news about KalVista Pharmaceuticals, Inc.

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	Apr. 22	CI
Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	Apr. 14	CI
Certain performance stock options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	Apr. 14	CI
Certain restricted stock units of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	Apr. 14	CI
Certain Stock Options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	Apr. 14	CI
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	Mar. 18	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 11	CI
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	Mar. 08	CI
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO	Mar. 07	MT
KalVista Pharmaceuticals, Inc. Announces Board Changes	Mar. 07	CI
KalVista Pharmaceuticals, Inc. Announces Chief Executive Officer Changes	Mar. 07	CI
KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency	Feb. 20	CI
Kalvista Pharmaceuticals Insider Sold Shares Worth $613,205, According to a Recent SEC Filing	Feb. 16	MT
Kalvista Pharmaceuticals Insider Sold Shares Worth $598,661, According to a Recent SEC Filing	Feb. 16	MT
Kalvista Pharmaceuticals Insider Sold Shares Worth $422,827, According to a Recent SEC Filing	Feb. 16	MT
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	Feb. 16	CI
HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $24 From $16, Maintains Buy Rating	Feb. 14	MT
KalVista Pharmaceuticals' Phase 3 Trial of Sebetralstat to Treat Hereditary Angioedema Meets All Endpoints; Shares Rise	Feb. 13	MT
Transcript : KalVista Pharmaceuticals, Inc. - Special Call	Feb. 13
KalVista meets main goals in late-stage trial for genetic disease	Feb. 13	RE
KalVista meets main goals in late-stage trial for skin condition treatment	Feb. 13	RE
Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema	Feb. 13	CI
Kalvista Pharmaceuticals Insider Sold Shares Worth $295,514, According to a Recent SEC Filing	Jan. 12	MT
Kalvista Pharmaceuticals Insider Sold Shares Worth $360,453, According to a Recent SEC Filing	Dec. 28	MT
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to NASDAQ Biotechnology Index	Dec. 18	CI

Chart KalVista Pharmaceuticals, Inc.

Duration

Period

More charts

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.

Sector

Pharmaceuticals

Calendar

2024-07-03 - Q4 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.78 USD

Average target price

30.6 USD

Spread / Average Target

+183.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
KALVISTA PHARMACEUTICALS, INC.	-12.00%	455M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals